LifeArc Early Ventures

LifeArc Early Ventures

Funds early-stage life science ventures with seed and Series A equity across therapeutics and medical device innovation.

LifeArc Early Ventures is the equity investment arm of LifeArc, a UK self-funded medical research charity that translates laboratory discoveries into treatments for rare diseases and global health conditions. Operating as LifeArc Ventures, the programme provides Seed and Series A equity investment to early-stage life science companies, with the possibility of significant follow-on investment reserved for successful portfolio companies. Investment coverage spans the full spectrum of therapeutics, HealthTech, and medical devices, focused within LifeArc's five strategic disease areas: Motor Neuron Disease and Rare Dementias, Chronic and Rare Respiratory Disease, Rare Disease, Childhood Cancer, and Global Health.

Beyond capital, portfolio companies gain access to LifeArc's scientific support infrastructure, including expert scientists and laboratory facilities at sites in Stevenage and Edinburgh, as well as strategic advice and industry connections built from LifeArc's decades of translational research experience. As of May 2026, LifeArc Early Ventures is listed as the single open funding call on LifeArc's current opportunities page — a signal that the programme is the primary vehicle through which LifeArc deploys external capital at any given time.

This is an equity investment programme, not a grant or loan call. Ticket size, detailed eligibility criteria, and the formal application process are not published on the LifeArc.org page; prospective applicants are directed to lifearcventures.com for full details. There is no fixed application deadline. Companies best positioned for this programme are early-stage life science ventures — typically UK-based but not explicitly restricted — with assets or platforms relevant to LifeArc's five disease focus areas, at the Seed or Series A stage, where LifeArc's scientific networks and translational expertise can add material value beyond the capital itself.